ABBV-141 for Healthy Adults
Trial Summary
What is the purpose of this trial?
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and immunogenicity after single ascending doses (SAD) of ABBV-141 in healthy adult Western and Asian participants.
Research Team
ABBVIE INC.
Principal Investigator
AbbVie
Eligibility Criteria
This trial is for healthy adults who are either Western or of specific Asian descent (Han Chinese or Japanese). Participants must be in good health as determined by medical exams, have a BMI between 18.0 and 32.0, and for Asians, they need to have parents/grandparents of the same descent.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single ascending dose of ABBV-141 or placebo via IV or SC administration
Follow-up
Participants are monitored for safety, pharmacokinetics, and immunogenicity after treatment
Treatment Details
Interventions
- ABBV-141
Find a Clinic Near You
Who Is Running the Clinical Trial?
AbbVie
Lead Sponsor
Dr. Roopal Thakkar
AbbVie
Chief Medical Officer since 2023
MD from Wayne State University School of Medicine
Robert A. Michael
AbbVie
Chief Executive Officer
Bachelor's degree in Finance from the University of Illinois